Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$239.26 USD

239.26
644,194

0.00 (0.00%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $239.18 -0.08 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

5 S&P 500 Winners of 100 Days of Coronavirus Pandemic

by Sweta Killa

Today marks 100 days since the World Health Organization declared COVID-19 a pandemic on Mar 11. We have highlighted some stocks from the S&P 500 index that soared more than 40% during this period.

Zacks Equity Research

Accuray's New CyberKnife S7 System to Boost Patient Care

by Zacks Equity Research

Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.

Tirthankar Chakraborty headshot

5 Best Stocks From 100 Days of Coronavirus

by Tirthankar Chakraborty

Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

Zacks Equity Research

Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk

by Zacks Equity Research

Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.

Zacks Equity Research

Here's Why You Should Hold on to Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Zacks Equity Research

AMN Healthcare (AMN) Introduces New Customizable Offering

by Zacks Equity Research

AMN Healthcare (AMN) offers a customizable return-to-work solutions as businesses resume operations amid the ongoing pandemic.

Zacks Equity Research

Here's Why You Should Add AngioDynamics to Your Portfolio

by Zacks Equity Research

AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.

Zacks Equity Research

HMS Holdings' Solution to Help Consumers Amid Coronavirus

by Zacks Equity Research

HMS Holdings (HMSY) offers a unique COVID-19 health management and communications solution to support consumers during the pandemic.

Sweta Killa headshot

Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?

by Sweta Killa

Smart Beta ETF report for JPME

Zacks Equity Research

DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

by Zacks Equity Research

DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

Zacks Equity Research

Zacks.com featured highlights include: The Clorox Company, West Pharmaceutical Services and Everbridge

by Zacks Equity Research

Zacks.com featured highlights include: The Clorox Company, West Pharmaceutical Services and Everbridge

Zacks Equity Research

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.

Zacks Equity Research

Top 3 Momentum Anomaly Stocks to Consider on Investor Optimism

by Zacks Equity Research

These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare Stock Now

by Zacks Equity Research

NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and solid recurring revenue base.

Zacks Equity Research

Ecolab's AdvaCare Disinfectant Receives First EPA Approval

by Zacks Equity Research

Ecolab's (ECL) AdvaCare Disinfectant receives first EPA approval for a laundry disinfectant and oxidizer emerging viral pathogen claim that is effective against the coronavirus.

Sanghamitra Saha headshot

4 Sector ETFs & Stocks to Buy on Record Jobs Gain in May

by Sanghamitra Saha

The U.S. jobs report for the month of May reflected the largest one-month job gains.

Zacks Equity Research

Why You Should Retain PerkinElmer (PKI) in Your Portfolio

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction from strong international presence and robust product portfolio.

Zacks Equity Research

Zacks.com featured highlights include: Synopsys, Tesla, Chemed, Teekay Tankers and West Pharmaceutical Services

by Zacks Equity Research

Zacks.com featured highlights include: Synopsys, Tesla, Chemed, Teekay Tankers and West Pharmaceutical Services

Zacks Equity Research

Cerner & NCHC Alliance to Boost Behavioral Health Technology

by Zacks Equity Research

Cerner (CERN) has been selected by NCHC to implement its EHR across three multi-specialty facilities.

Zacks Equity Research

Buy These 5 Low Leverage Stocks to Invest Safely

by Zacks Equity Research

Debt financing is a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate

Zacks Equity Research

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

Zacks Equity Research

Zacks.com featured highlights include: West Pharmaceutical Services, Teradyne, Dollar General, Applied Materials and Kroger

by Zacks Equity Research

Zacks.com featured highlights include: West Pharmaceutical Services, Teradyne, Dollar General, Applied Materials and Kroger

Zacks Equity Research

Here's Why You Should Invest in OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain traction from solid prospects in RAYALDEE and BioReference platforms.

Sweta Killa headshot

Looking for Dividend Growth? Here Are 5 Solid Picks

by Sweta Killa

Investors are once again in search for consistent and safe income in a near-zero interest environment, a series of drastic dividend cuts and rising U.S.-China tension.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.